Peter Junker

6.4k total citations
180 papers, 4.0k citations indexed

About

Peter Junker is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Peter Junker has authored 180 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 103 papers in Rheumatology, 48 papers in Immunology and 27 papers in Hematology. Recurrent topics in Peter Junker's work include Rheumatoid Arthritis Research and Therapies (65 papers), Systemic Lupus Erythematosus Research (43 papers) and Monoclonal and Polyclonal Antibodies Research (19 papers). Peter Junker is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (65 papers), Systemic Lupus Erythematosus Research (43 papers) and Monoclonal and Polyclonal Antibodies Research (19 papers). Peter Junker collaborates with scholars based in Denmark, United States and Sweden. Peter Junker's co-authors include Kim Hørslev‐Petersen, Anne Voss, Anders Jørgen Svendsen, Mikkel Østergaard, Merete Lund Hetland, Hanne Lindegaard, Helle Laustrup, I. Lorenzen, Kristian Stengaard‐Pedersen and Hans Carl Hasselbalch and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Gut.

In The Last Decade

Peter Junker

175 papers receiving 3.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Peter Junker Denmark 34 2.0k 1.3k 648 620 437 180 4.0k
Shigeto Tohma Japan 33 1.6k 0.8× 968 0.7× 578 0.9× 408 0.7× 354 0.8× 182 3.5k
Christophe Richez France 37 2.4k 1.2× 2.2k 1.7× 618 1.0× 560 0.9× 737 1.7× 148 4.6k
Corinne Miceli‐Richard France 39 2.0k 1.0× 2.0k 1.5× 735 1.1× 512 0.8× 399 0.9× 112 4.6k
John J. Cush United States 31 2.5k 1.3× 1.6k 1.2× 529 0.8× 1.2k 1.9× 461 1.1× 59 4.3k
Carlos Abud‐Mendoza Mexico 33 2.7k 1.3× 2.1k 1.6× 328 0.5× 605 1.0× 278 0.6× 130 4.5k
Hideto Kameda Japan 38 2.6k 1.3× 1.2k 0.9× 411 0.6× 1.2k 1.9× 398 0.9× 196 4.3k
Arnaud Constantin France 30 1.9k 1.0× 829 0.6× 427 0.7× 605 1.0× 335 0.8× 120 3.1k
Gian Domenico Sebastiani Italy 30 3.1k 1.5× 1.9k 1.4× 571 0.9× 560 0.9× 268 0.6× 109 4.3k
Carrie Wagner United States 33 1.9k 1.0× 1.8k 1.4× 538 0.8× 936 1.5× 314 0.7× 53 4.8k
L B van de Putte Netherlands 35 3.5k 1.7× 1.2k 0.9× 694 1.1× 969 1.6× 393 0.9× 79 5.2k

Countries citing papers authored by Peter Junker

Since Specialization
Citations

This map shows the geographic impact of Peter Junker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Junker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Junker more than expected).

Fields of papers citing papers by Peter Junker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Junker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Junker. The network helps show where Peter Junker may publish in the future.

Co-authorship network of co-authors of Peter Junker

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Junker. A scholar is included among the top collaborators of Peter Junker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Junker. Peter Junker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Greisen, Stinne Ravn, Kristian Stengaard‐Pedersen, Peter Junker, et al.. (2024). Plasma haem oxygenase-1 may represent a first-in-class biomarker of oxidative stress in rheumatoid arthritis. Scandinavian Journal of Rheumatology. 54(3). 153–157. 1 indexed citations
2.
Mehta, Akul Y., Kristian Stengaard‐Pedersen, Pierre Busson, et al.. (2023). Increased Galectin-9 Levels Correlate with Disease Activity in Patients with DMARD-Naïve Rheumatoid Arthritis and Modulate the Secretion of MCP-1 and IL-6 from Synovial Fibroblasts. Cells. 12(2). 327–327. 7 indexed citations
3.
Hansen, Aida S., Kristian Juul‐Madsen, Peter Junker, et al.. (2023). Lymphocyte activation gene 3 is increased and affects cytokine production in rheumatoid arthritis. Arthritis Research & Therapy. 25(1). 97–97. 7 indexed citations
4.
Stengaard‐Pedersen, Kristian, Merete Lund Hetland, Kim Hørslev‐Petersen, et al.. (2022). Baseline serum levels of IgA anti-cyclic citrullinated protein antibodies in early rheumatoid arthritis predict radiographic progression after 11 years of treatment: a secondary analysis of the CIMESTRA study. Scandinavian Journal of Rheumatology. 52(5). 493–497. 2 indexed citations
5.
Hetland, Merete Lund, Kim Hørslev‐Petersen, Lykke Midtbøll Ørnbjerg, et al.. (2022). Serum 14-3-3η as predictor of clinical remission and progression of structural damage in early rheumatoid arthritis following a treat-to-target strategy in a randomized controlled trial. Scandinavian Journal of Rheumatology. 52(4). 342–352. 2 indexed citations
6.
Greisen, Stinne Ravn, Merete Lund Hetland, Mikkel Østergaard, et al.. (2021). CXCL13 predicts long-term radiographic status in early rheumatoid arthritis. Lara D. Veeken. 61(6). 2590–2595. 10 indexed citations
7.
Stengaard‐Pedersen, Kristian, Brian Bridal Løgstrup, Kim Hørslev‐Petersen, et al.. (2021). Similar lipid level changes in early rheumatoid arthritis patients following 1-year treat-to-target strategy with adalimumab plus methotrexate versus placebo plus methotrexate: secondary analyses from the randomised controlled OPERA trial. Rheumatology International. 41(3). 543–549. 6 indexed citations
8.
Stengaard‐Pedersen, Kristian, Peter Vestergaard, Robin Christensen, et al.. (2020). Impact of season on the association between vitamin D levels at diagnosis and one-year remission in early Rheumatoid Arthritis. Scientific Reports. 10(1). 7371–7371. 8 indexed citations
9.
Sundin, Ulf, Mikkel Østergaard, Daniel Glinatsi, et al.. (2019). Validity and Responsiveness of Combined Inflammation and Combined Joint Damage Scores Based on the OMERACT Rheumatoid Arthritis MRI Scoring System (RAMRIS). The Journal of Rheumatology. 46(9). 1222–1227. 6 indexed citations
10.
Stengaard‐Pedersen, Kristian, Peter Vestergaard, Mikkel Østergaard, et al.. (2018). The D‐vitamin metabolite 1,25(OH)2D in serum is associated with disease activity and Anti‐Citrullinated Protein Antibodies in active and treatment naïve, early Rheumatoid Arthritis Patients. Scandinavian Journal of Immunology. 88(3). e12704–e12704. 18 indexed citations
11.
Loft, Anne Gitte, Heidi Lausten Munk, Leona Gilbert, et al.. (2016). No diagnostic utility of antibody patterns against Klebsiella pneumoniae capsular serotypes in patients with axial spondyloarthritis vs. patients with non-specific low back pain: a cross-sectional study. Scandinavian Journal of Rheumatology. 46(4). 296–302. 6 indexed citations
12.
Stengaard‐Pedersen, K., Magnus Christian Lydolph, Finn Somnier, & Peter Junker. (2016). [Myopathy in a patient during simvastatin and fluconazole treatment].. PubMed. 178(39). 1 indexed citations
13.
Svendsen, Anders Jørgen, Kristina Gervin, Robert Lyle, et al.. (2016). Differentially Methylated DNA Regions in Monozygotic Twin Pairs Discordant for Rheumatoid Arthritis: An Epigenome-Wide Study. Frontiers in Immunology. 7. 510–510. 33 indexed citations
14.
Svendsen, Anders Jørgen, Jacob Hjelmborg, Kirsten Ohm Kyvik, et al.. (2013). The impact of genes on the occurrence of autoantibodies in rheumatoid arthritis. A study on disease discordant twin pairs. Journal of Autoimmunity. 41. 120–125. 21 indexed citations
15.
Ammitzbøll, Christian Gytz, Jens Christian Jensenius, Torkell Ellingsen, et al.. (2012). M-Ficolin, an activator of the complement system is the strongest predictor of both DAS28 remission and low disease activity in a cohort of 180 early DMARD naïve rheumatoid arthritis patients followed in The OPERA-study.. University of Southern Denmark Research Portal (University of Southern Denmark). 64(10). 1 indexed citations
16.
Hørslev‐Petersen, Kim, Merete Lund Hetland, Peter Junker, et al.. (2011). Adalimumab Added to Methotrexate and Intra-Articular Glucocorticoid Increases Remission Rates At One Year In Early, DMARD-Naïve Patients with Rheumatoid Arthritis—An Investigator-Initiated Randomized, Controlled, Double-Blinded Study. Research at the University of Copenhagen (University of Copenhagen). 63. 147–147. 3 indexed citations
17.
Østergaard, Mikkel, Uffe Møller Døhn, Anne Duer‐Jensen, et al.. (2011). Patterns of Magnetic Resonance Imaging Bone Erosion in Rheumatoid Arthritis — Which Bones Are Most Frequently Involved and Show the Most Change?: Figure 1.. The Journal of Rheumatology. 38(9). 2014–2017. 15 indexed citations
18.
Edén, Michael, et al.. (2008). LAND PROPERTY DISTRIBUTIONS AS A MEANS FOR ENHANCING SUSTAINABLE BUILDING. THE LUNDBY COMPETITION IN GOTHENBURG, SWEDEN, AS AN EXAMPLE. Chalmers Publication Library (Chalmers University of Technology).
19.
Hetland, Merete Lund, M. Østergaard, A Vestergaard, et al.. (2007). Is it possible to stop radiographic progression with conventional treatment in early rheumatoid arthritis?: 2 years results from the CIMESTRA study. Annals of the Rheumatic Diseases. 1 indexed citations
20.
Kjeldsen, Jens, Ove B. Schaffalitzky de Muckadell, & Peter Junker. (1995). Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.. Gut. 37(6). 805–810. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shigeto Tohma Breakdown of academic impact, for papers by Christophe Richez Breakdown of academic impact, for papers by Corinne Miceli‐Richard Breakdown of academic impact, for papers by John J. Cush Breakdown of academic impact, for papers by Carlos Abud‐Mendoza Breakdown of academic impact, for papers by Hideto Kameda Breakdown of academic impact, for papers by Arnaud Constantin Breakdown of academic impact, for papers by Gian Domenico Sebastiani Breakdown of academic impact, for papers by Carrie Wagner Breakdown of academic impact, for papers by L B van de Putte
Rankless by CCL
2026